Ottobock SE & Co. KGaA
ISIN: DE000BCK2223
WKN: BCK222
13 July 2026 10:00AM

dynion explore: new prosthetic knee joint for adolescents.

Ottobock SE & Co. KGaA · ISIN: DE000BCK2223 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2363624


EQS-Media / 13.07.2026 / 10:00 CET/CEST

dynion explore: new prosthetic knee joint for adolescents.

Monday, 13 July 2026
-----------------------------

Ottobock expands its prosthetics portfolio.

With Ottobock’s latest hydraulic prosthetic knee joint, the dynion explore, the global market leader is closing a treatment gap: Until now, active adolescents and adults with a low body weight have had few suitable options that support their active lifestyle while providing the necessary level of safety.

“We want to make high-quality mobility solutions available throughout all stages of life. That is why we are specifically expanding our portfolio to serve a group of users who have previously been underserved. In doing so, we pursue our goal of providing our users with integrated fitting solutions throughout their lives,” says Arne Jörn, Chief Operating and Chief Technology Officer (COO/CTO) at Ottobock.

Following its world premiere at OTWorld 2026 in Leipzig, Germany, the dynion explore will now be gradually launched, beginning in Europe, the United States and China. In Asia in particular, there is greater demand for compact solutions due to users’ generally smaller stature.

This is part of an integrated treatment approach that keeps pace with life.

The dynion explore enables a seamless transition from pediatric prosthetic knee joints to adult fittings: The new device makes it easier for adolescents to transition to larger microprocessor-controlled knee joints, such as the Genium X4, later in life, as they become accustomed to walking with stance phase control at an early stage. This provides high-quality treatment across all phases of life – from infancy to early adulthood. Users also benefit from a complete solution from a single source: For example, the dynion explore can be combined with the customised iconiq 3D-printed silicone liner, the Quickchange adapter and the Taleo or Evanto prosthetic feet.

Developed for an active lifestyle – robust, versatile, reliable.

An active, self-determined life means movement, spontaneity and versatility – especially for adolescents. People weighing up to 60 kilograms can now benefit from the compact design of the new prosthetic knee joint, which was developed specifically for highly active users. The dynion explore combines powerful rotation hydraulics with stance phase control specifically designed for users with a low body weight. This allows users to walk in a controlled yet dynamic manner, even at varying speeds and with different requirements, such as short sprints to the bus stop or outdoor activities. Thanks to stance phase control, the prosthetic knee joint flexes in a controlled manner, even under load, providing support when walking down stairs and slopes, as well as when bending down to pick up a school bag or briefcase, for example. The manual lock makes relaxed standing possible.

With functions such as cycling mode that can be activated at the touch of a button and water resistance, the aluminium mechanical knee joint is designed for an active and varied lifestyle. It is resistant to fresh, salt and chlorinated water, making it ideal for the beach or swimming pool. Various colour options provide a unique, personalised look.

***

Contact
Ottobock SE & Co. KGaA
Corporate Communications

Nadine Winter
Phone: +49 1511 888 3507
nadine.winter@ottobock.de


About Ottobock 

Ottobock, a listed global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalization of the industry. Founded in Berlin in 1919, the company has business activities in 45 countries with nearly 9,300 employees (FTEs) worldwide and operates the largest international patient care network with around 420 patient care clinics. Ottobock is shaping the future of human bionics with a strong R&D ratio in the products and components business and over 2,600 patents and patent applications. Ottobock’s mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988. 

 



End of Media Release


Issuer: Ottobock SE & Co. KGaA
Key word(s): Health

13.07.2026 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Ottobock SE & Co. KGaA
Max-Näder-Straße 15
37115 Duderstadt
Germany
Phone: +49 5527 848 - 0
E-mail: info@ottobock.com
Internet: https://corporate.ottobock.com
ISIN: DE000BCK2223
WKN: BCK222
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange
EQS News ID: 2363624

 
End of News EQS Media

2363624  13.07.2026 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2020 2021 2022 2023 2024 2025 2026e
Sales1 0,00 1.187,51 1.333,19 1.495,04 1.604,60 1.679,80 1.790,00
EBITDA1,2 0,00 162,12 1.963,35 248,70 299,20 371,80 440,00
EBITDA-Margin3 0,00 0,00 14,85 16,64 18,65 22,13 24,58
EBIT1,4 0,00 0,00 -934,00 -27,00 290,00 0,00 256,00
EBIT-Margin5 0,00 0,00 0,00 -1,81 18,07 11,07 14,30
Net Profit (Loss)1 0,00 19,63 75,33 48,10 27,90 88,30 140,00
Net-Margin6 0,00 0,00 5,64 3,22 1,74 5,26 7,82
Cashflow1,7 0,00 0,00 82,00 197,80 275,10 333,20 0,00
Earnings per share8 0,00 0,00 1,17 0,75 0,44 1,44 2,10
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,97 1,05
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Ottobock
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
BCK222 DE000BCK2223 SE & Co. KGaA 3.660,24 Mio € 09.10.2025 9F3GG68Q+78
* * *
PE 2027e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
23,83 27,24 0,88 44,00 11,16 10,99 2,18
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,00 0,97 1,70%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
19.05.2026 06.05.2026 13.08.2026 12.11.2026 19.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+1,96%
57,20 €
ATH 76,35 €
+5,83% -4,83% -12,34% +0,00% -13,33%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2026          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 by Gereon Kruse #BGFL